From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer. Fukuda A, Okuma Y. Clin Cancer Res 2024 May 20. doi: 10.1158/1078-0432.CCR-23-4035.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fukuda A, Okuma Y. From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res 2024 May 20. doi: 10.1158/1078-0432.CCR-23-4035.
PMID: 38767589